180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 25,900 shares, a decrease of 50.4% from the January 31st total of 52,200 shares. Based on an average daily trading volume, of 409,700 shares, the short-interest ratio is currently 0.1 days. Currently, 1.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 180 Life Sciences in a research note on Wednesday, February 19th.

180 Life Sciences Price Performance

Shares of ATNF opened at $1.17 on Friday. The business’s 50-day moving average is $1.57 and its two-hundred day moving average is $2.09. 180 Life Sciences has a fifty-two week low of $1.10 and a fifty-two week high of $17.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC bought a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned approximately 2.20% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is owned by institutional investors and hedge funds.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.